Bide Pharmatech Co. Ltd. A Total Assets
Bide Pharmatech Co. Ltd. A total assets. Based on the latest financial reports, Bide Pharmatech Co. Ltd. A (688073) holds total assets worth CN¥2.54 Billion CNY (≈ $371.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 688073 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Bide Pharmatech Co. Ltd. A (2020–2025)
Total assets of Bide Pharmatech Co. Ltd. A from 2020 to 2025. This chart illustrates how Bide Pharmatech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See Bide Pharmatech Co. Ltd. A share price for real-time trading data and today's change.
Bide Pharmatech Co. Ltd. A - Asset Composition Analysis
Bide Pharmatech Co. Ltd. A Total Assets Breakdown (December 2025)
Bide Pharmatech Co. Ltd. A total assets breakdown as of December 2025. Bide Pharmatech Co. Ltd. A's total assets of CN¥2.54 Billion consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 37.4% |
| Accounts Receivable | CN¥253.44 Million | 10.1% |
| Inventory | CN¥962.01 Million | 38.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥4.93 Million | 0.2% |
| Goodwill | CN¥7.56 Million | 0.3% |
Asset Composition Trend (2020–2025)
This chart illustrates how Bide Pharmatech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Bide Pharmatech Co. Ltd. A short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bide Pharmatech Co. Ltd. A's current assets represent 91.6% of total assets in 2025, an increase from 85.9% in 2020.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2025, up from 17.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 38.2% of total assets.
Bide Pharmatech Co. Ltd. A Competitors by Total Assets
Key competitors of Bide Pharmatech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Bide Pharmatech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.43 | 2.88 | 7.65 |
| Quick Ratio | 4.37 | 1.52 | 5.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.03 Billion | CN¥1.11 Billion | CN¥1.91 Billion |
Bide Pharmatech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Bide Pharmatech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.56 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | CN¥2.52 Billion |
| Market Capitalization | $890.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bide Pharmatech Co. Ltd. A's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bide Pharmatech Co. Ltd. A's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bide Pharmatech Co. Ltd. A (2020–2025)
The table below shows the annual total assets of Bide Pharmatech Co. Ltd. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.52 Billion ≈ $368.29 Million |
+4.08% |
| 2024-12-31 | CN¥2.42 Billion ≈ $353.83 Million |
+0.12% |
| 2023-12-31 | CN¥2.42 Billion ≈ $353.39 Million |
+2.37% |
| 2022-12-31 | CN¥2.36 Billion ≈ $345.23 Million |
+160.36% |
| 2021-12-31 | CN¥906.13 Million ≈ $132.60 Million |
+70.36% |
| 2020-12-31 | CN¥531.90 Million ≈ $77.83 Million |
-- |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.